A Phase I/II, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours.

Inclusion Criteria:

- Histological or cytological confirmation of an advanced solid malignant tumour (or
lymphoma Part A only)

- Cancer which is refractory to standard therapies or for which no standard therapy
exists, patients with measurable or non-measurable disease (according to RECIST
criteria) can be recruited to Part A

- Evidence of post-menopausal status or negative urine/serum pregnancy test for
pre-menopausal female patients

Exclusion Criteria:

- Patients with severe laboratory abnormalities for haematology, liver or renal
function. Also treatment with any haemopoietic growth factors are not allowed within
two weeks from first dose of study drug.

- Patients with abnormal fasting glucose, have type I or II Diabetes or have
uncontrolled blood fats and cholesterol

- Patients with a history of neurological disease, peripheral or central neuropathy,
brain metastases or family history of myopathy are excluded

- Patients with severe cardiac condition of ischemia, impaired ventricular function and
arrhythmias, evidence of severe or uncontrolled systemic or current unstable or
uncompensated respiratory or cardiac conditions